LifePoint Hospitals 2013 D&A higher than expected, says UBS UBS said LifePoint advised for higher 2013 D&A of $30B-$35B, substantially higher than expected and as much as a 25c earnings headwind in 2013. Shares are Neutral rated with a $39 price target.
LifePoint Hospitals upgraded at RW Baird As previously reported, Baird upgraded LifePoint to Outperform from Neutral. The firm upgraded shares based on valuation, M&A pipeline momentum, improved core operations, and potential further ACA benefit. Price target raised to $76 from $70.